Related Experiment Videos
Liver transplantation for alpha-1-antitrypsin deficiency in children
A A Prachalias1, M Kalife, R Francavilla
1Liver Transplant Surgical Service, King's College Hospital, Denmark Hill, London, UK.
Insights
Alpha-1-antitrypsin (a1-AT) deficiency, a genetic liver disease, affects Caucasian children. Liver transplantation offers a definitive treatment, with excellent outcomes when performed promptly.
Area of Science:
- Genetics
- Hepatology
- Pediatric Gastroenterology
Background:
- Alpha-1-antitrypsin (a1-AT) deficiency is an inherited metabolic disorder.
- It is a leading cause of genetic liver disease, particularly in Caucasians.
- This condition can lead to end-stage liver disease in children.
Purpose of the Study:
- To review the clinical experience with pediatric patients suffering from end-stage liver disease due to a1-AT deficiency.
- To evaluate the efficacy of liver transplantation as a treatment modality.
Main Methods:
- Retrospective review of 21 pediatric patients with a1-AT deficiency (PIZZ genotype).
- Analysis of clinical presentation, treatment interventions (liver transplantation), and patient outcomes.
- Median follow-up duration of 40 months.
Main Results:
- All 21 patients had the PIZZ genotype.
- Nineteen presented with neonatal jaundice; two with childhood hepatosplenomegaly.
- Twenty-five liver transplantations were performed across the cohort.
- All patients are alive post-transplantation.
Conclusions:
- Liver transplantation is the only definitive treatment for end-stage liver disease caused by a1-AT deficiency in children.
- Excellent patient survival rates are achievable.
- Reducing transplant waiting times and early referral are crucial for optimal outcomes.
Abstract:
Alpha-1-antitrypsin (a1-AT) deficiency is an inborn error of metabolism, which can cause liver disease. The condition is one of the most common genetic disorders in the Caucasian population. Here we review our experience with 21 children suffering from end-stage liver disease due to a1-AT deficiency. All children are PIZZ homozygotes. Nineteen of them initially presented with neonatal jaundice and two with hepatosplenomegaly in childhood. Twenty-five liver transplantations were performed. All children are currently alive at a median followup of 40 months. Liver replacement provides the only definite treatment for children with end-stage liver disease associated with a1-AT deficiency. Excellent results can be achieved by reducing waiting time for transplantation and by early referral to a liver transplant centre.